Phase 4 N=137 Evaluating Vitamin D3 Supplement on Post-Op Outcomes
Knee Osteoarthritis
Primary: Knee Society Score (KSS), Functional Component (2012) at 3 Weeks Post Operative — 46.94; 50.89 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Cardiogenic Shock Intravascular Cooling Trial
Cardiogenic Shock
Primary: Number of Participants With Episodes of Arrhythmia — 0; 1 Participants — p=1
Phase 3 N=993 Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
RSV
Primary: Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of…
Phase 2 N=5 RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Age Related Macular Degeneration
Primary: Macular Edema — 416 Microns
Phase 3 N=230 Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate — 65; 66 participants
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
N/A N=161 Virtual Immersive Communication Training on Recommending Immunizations
Human Papilloma Virus
Primary: Percent Change From Baseline in the Percentage of Participants With HPV Vaccine Initiation — 18.1; 3.9 Percent Change from Baseline
Phase 2 N=4 Study of Vitamin D in Children With Sickle Cell Disease
Sickle Cell Disease
Primary: Serum 25-hydroxyvitamin D Concentration — 28.5; 36.5; 41.0; 41.75 ng/mL
N/A N=19 Telerehabilitation Early After Stroke
Stroke
Primary: Change in Fugl-Meyer Arm Motor Score From Baseline to End of Treatment (60 Days) — 18.07 units on a scale
Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
N/A N=10 Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
Painful Diabetic Neuropathy
Primary: Pain Assessment — 6.5; 1.0 score on a scale
Phase 2 N=6 A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
Arterial Ischemic Stroke
Primary: Changes in Volume of Infarct — 9.97; 4.06 mL — p=0.0313
N/A N=242 Preparation for End-of-Life Decision Making in Mild Dementia
Dementia
Primary: Dyad Congruence With Goals-of-Care Tool — 9; 4; 11; 24 Participants
Phase 2 N=51 Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Leukemia
Primary: Maximum Tolerated Dose of Intensity-modulated Radiotherapy (Phase I) — 2000 cGy
Phase 4 N=60 Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Anxiety Disorder
Primary: Magnitude of Startle Reflex During Safe Condition — 42.2880893; 42.39801; 43.61243; 44.1886408 millivolts (mV)